CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
ctdna
A collection of 17 issues
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
Skip to content
The CRC Digest
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open)
This content is informational only and does not constitute medical advice.
Always consult
ctDNA clearance as early biomarker in KRAS G12C colorectal cancer
Skip to content
The CRC Digest
ctDNA clearance as early biomarker in KRAS G12C colorectal cancer
Phase 3 CodeBreaK 300 results link circulating tumor DNA clearance to efficacy and prognosis with sotorasib plus panitumumab. (JCO)
This content is informational only and does not constitute medical advice.
Always consult your oncologist
CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
Practical guidance for integrating ctDNA testing into clinical care
Skip to content
The CRC Digest
Practical guidance for integrating ctDNA testing into clinical care
A narrative review summarizes evidence for ctDNA minimal residual disease testing in gastrointestinal cancers, with strongest data supporting use in resected stage II colon cancer. (Clinical and Translational Oncology)
This content is informational only and
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence
Skip to content
The CRC Digest
Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence
A review of current evidence suggests circulating tumor DNA has significant prognostic and predictive potential for detecting minimal residual disease and individualizing adjuvant therapy in colorectal cancer. (Klinická Onkologie)
This content is informational only
CRC Research Update — April 20, 2026
Today's colorectal cancer research highlights